首页> 外文期刊>Bone marrow transplantation >Nonmyeloablative allogeneic peripheral blood stem cell transplantation for multifocal extramedullary plasmacytomas progressing after autologous transplantation.
【24h】

Nonmyeloablative allogeneic peripheral blood stem cell transplantation for multifocal extramedullary plasmacytomas progressing after autologous transplantation.

机译:自体移植后非清髓性异体外周血干细胞移植治疗多灶性髓外浆细胞瘤的进展。

获取原文
获取原文并翻译 | 示例
       

摘要

Multifocal extramedullary plasmacytomas (EMP) are an uncommon manifestation of plasma cell malignancies. We report two patients with multiple EMP who developed rapidly progressive and ultimately fatal disease shortly after undergoing nonmyeloablative, matched-related donor allogeneic peripheral blood stem cell transplantation (PBSCT). We have not observed a similar course in patients transplanted for multiple myeloma without extramedullary manifestations and hypothesize that the intense immunosuppression associated with the fludarabine, busulfan and anti-thymocyte globulin conditioning regimen may have contributed to rapid disease progression in the two EMP patients. Our observations support the assertion that extramedullary disease is a marker for an aggressive, refractory plasma cell malignancy and suggest that patients should be treated intensively from the time of diagnosis. The utility of a graft-versus-tumor effect and the role of nonmyeloablative allogeneic PBSCT is yet to be defined in patients with extramedullary plasma cell malignancies, but it is logical to consider using it at the time of minimal residual disease rather than at disease relapse or progression. Nevertheless, we recommend circumspection in the administration of highly immunosuppressive conditioning regimens to patients with refractory EMP and encourage further clinical research in this area.
机译:多灶性髓外浆细胞瘤(EMP)是浆细胞恶性肿瘤的罕见表现。我们报告了两名患有多种EMP的患者,在接受非清髓性,匹配相关的供体同种异体外周血干细胞移植(PBSCT)后不久,他们迅速发展为最终致命疾病。我们没有在没有髓外表现的多发性骨髓瘤移植患者中观察到类似的病程,并假设与氟达拉滨,白消安和抗胸腺细胞球蛋白调节方案相关的强烈免疫抑制可能导致了两名EMP患者的疾病快速进展。我们的观察结果支持髓外疾病是侵袭性,难治性浆细胞恶性肿瘤的标志,并建议从确诊之日起就应对患者进行强化治疗。对于髓外浆细胞恶性肿瘤患者,尚需确定移植抗肿瘤作用的有效性和非清髓性同种异体PBSCT的作用,但考虑将其用于残留最小的疾病而不是疾病复发时考虑使用是合乎逻辑的或进展。然而,我们建议对难治性EMP患者进行高度免疫抑制条件治疗时应谨慎行事,并鼓励该领域的进一步临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号